| Sep 20 |
Johnson & Johnson (NYSE:JNJ) Sees Robust Q2 Sales Growth and Strategic FDA Approvals, But Faces MedTech Challenges
|
| Sep 20 |
J&J said to boost offer to settle baby powder lawsuits to over $8.2B
|
| Sep 19 |
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
|
| Sep 19 |
The Latest Analyst Ratings For Johnson & Johnson
|
| Sep 18 |
J&J threatened with sanctions over plan to rebate 340B drugs
|
| Sep 18 |
Johnson & Johnson (JNJ) Faces Legal Challenges While Advancing MedTech Innovations for Growth
|
| Sep 17 |
U.S. To J&J: Don't Target Hospital Drug Discounts
|
| Sep 16 |
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
|
| Sep 16 |
Johnson & Johnson Gets $260 Million Talc Verdict Overturned
|
| Sep 16 |
J&J gets $260 million talc verdict overturned in Oregon, new trial ordered
|
